These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11391594)

  • 21. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers.
    Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
    Clin Cancer Res; 1996 Oct; 2(10):1795-800. PubMed ID: 9816132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer.
    Van der Poel HG; Van Balken MR; Schamhart DH; Peelen P; de Reijke T; Debruyne FM; Schalken JA; Witjes JA
    Urology; 1998 Jan; 51(1):44-50. PubMed ID: 9457287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors].
    Noël N; Couteau J; Maillet G; Gobet F; d'Aloisio F; Minier C; Pfister C
    Prog Urol; 2013 Jan; 23(1):29-35. PubMed ID: 23287481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity.
    Kavaler E; Landman J; Chang Y; Droller MJ; Liu BC
    Cancer; 1998 Feb; 82(4):708-14. PubMed ID: 9477104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization.
    Okamura T; Umemoto Y; Yasui T; Saiki S; Kuroda H; Kotoh S; Kamizaki H
    Int J Clin Oncol; 2004 Oct; 9(5):373-7. PubMed ID: 15549587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes.
    Sourvinos G; Kazanis I; Delakas D; Cranidis A; Spandidos DA
    J Urol; 2001 Jan; 165(1):249-52. PubMed ID: 11125419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voided urine flow cytometry in screening high-risk patients for the presence of bladder cancer.
    Hermansen DK; Badalament RA; Bretton PR; Kimmel M; Aswad CM; Whitmore WF; Melamed MR
    J Occup Med; 1990 Sep; 32(9):894-7. PubMed ID: 2074515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can sensitivity of voided urinary cytology or bladder wash cytology be improved by the use of different urinary portions?
    Mungan NA; Kulacoglu S; Basar M; Sahin M; Witjes JA
    Urol Int; 1999; 62(4):209-12. PubMed ID: 10567884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.
    Retz M; Lehmann J; Amann E; Wullich B; Röder C; Stöckle M
    J Urol; 2003 Jan; 169(1):86-9. PubMed ID: 12478110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A comparative study of the sensitivity of bladder washing flow cytometry, voided urine cytology and bladder washing cytology in the detection of bladder carcinoma].
    Tachibana M; Jitsukawa S; Tazaki H; Tashiro Y
    Nihon Hinyokika Gakkai Zasshi; 1989 Jul; 80(7):1025-30. PubMed ID: 2607716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 gene mutation in recurrent superficial bladder cancer.
    Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
    J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive voided urine cytology predicts worse pathological findings of nephroureterectomy specimens in patients with upper tract urothelial carcinoma: does selective ureteral cytology have an additional efficacy?
    Sakano S; Inamoto T; Inoue R; Matsumoto H; Nagao K; Yamamoto Y; Azuma H; Matsuyama H
    Jpn J Clin Oncol; 2015 Oct; 45(10):968-72. PubMed ID: 26232447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
    Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
    J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
    Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
    Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of mutations in the p53 gene in superficial bladder cancer.
    Dahse R; Utting M; Werner W; Schubert J; Claussen U; Junker K
    Oncol Rep; 2000; 7(5):931-6. PubMed ID: 10948316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.